A solid-phase glycosyltransferase assay for high-throughput screening in drug discovery research |
| |
Authors: | Rob S. Donovan Alessandro Datti Myung-Gi Baek Qingquan Wu Ian J. Sas Bozena Korczak Eric G. Berger René Roy James W. Dennis |
| |
Affiliation: | (1) GlycoDesign Inc., 480 University Ave., Suite 900, Toronto, ON, Canada, M5G 1V2;(2) Department of Chemistry, University of Ottawa, Ottawa, ON, Canada, K1N 6N5;(3) Institute of Physiology, University of Zurich, Winterthurerstrasse 190, CH-8057 Zurich, Switzerland;(4) Samuel Lunenfeld Research Institute, Mount Sinai Hospital, 600 University Ave, M5G 1X5, and;(5) Department of Molecular and Medical Genetics, University of Toronto, Toronto, ON |
| |
Abstract: | Glycosyltransferases mediate changes in glycosylation patterns which, in turn, may affect the function of glycoproteins and/or glycolipids and, further downstream, processes of development, differentiation, transformation and cell-cell recognition. Such enzymes, therefore, represent valid targets for drug discovery. We have developed a solid-phase glycosyltransferase assay for use in a robotic high-throughput format. Carbohydrate acceptors coupled covalently to polyacrylamide are coated onto 96-well plastic plates. The glycosyltransferase reaction is performed with recombinant enzymes and radiolabeled sugar-nucleotide donor at 37°C, followed by washing, addition of scintillation counting fluid, and measurement of radioactivity using a 96-well -counter. Glycopolymer construction and coating of the plastic plates, enzyme and substrate concentrations, and linearity with time were optimized using recombinant Core 2 1-6-N-acetylglucosaminyltransferase (Core 2 GlcNAc-T). This enzyme catalyzes a rate-limiting reaction for expression of polylactosamine and the selectin ligand sialyl-Lewisx in -glycans. A glycopolymer acceptor for 1-6-N-acetylglucosaminyltransferase V was also designed and shown to be effective in the solid-phase assay. In a high-throughput screen of a microbial extract library, the coefficient of variance for positive controls was 9.4%, and high concordance for hit validation was observed between the Core 2 GlcNAc-T solid-phase assay and a standard solution-phase assay. The solid-phase assay format, which can be adapted for a variety of glycosyltransferase enzymes, allowed a 5–6 fold increase in throughput compared to the corresponding solution-phase assay. |
| |
Keywords: | glycosyltransferase assay high-throughput screening drug discovery |
本文献已被 PubMed SpringerLink 等数据库收录! |
|